PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast: Recent Episodes
PVI, PeerView Institute for Medical Education
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.
Go online to PeerView.com/HZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding use of CD38 antibodies, CAR-T, and BCMA and non-BCMA treatment options has quickly changed the clinical conversation for modern multiple myeloma (MM) management. Are you prepared for the new “ABCs” of myeloma care? Find out by accessing this PeerView MasterClass and Case Forum event developed in collaboration with the HealthTree Foundation for Multiple Myeloma and recorded at the 2023 ASCO Annual Meeting. During this activity, our experts provide insights and case-based guidance on therapy selection, dosing, scheduling, and management of treatment-related AEs with CD38 antibodies and BCMA platforms in MM. Learn the real-world “ABCs” of treatment innovation in MM, and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize the unique MOA and safety/efficacy evidence supporting the use of CD38 and BCMA-targeting antibodies, CAR-T therapy, and other innovative compounds across multiple myeloma treatment settings; Develop personalized upfront and sequential treatment plans with innovative antibody and immunotherapy platforms, based on relevant prognostic information and safety considerations; and Address practical aspects of multiple myeloma care when using antibody and immunotherapy platforms, including dosing, scheduling, patient referral to specialized care, education, counseling, and unique treatment-related toxicities
Go online to PeerView.com/ERY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hundreds of thousands of organ transplant recipients living in the United States, who must take immunosuppressive medication, are at an increased risk of COVID-19 infection. Tixagevimab co-packaged with cilgavimab has lost its emergency use authorization as prevention for immunocompromised patients because of its lack of efficacy against newer variants. In the absence of prevention agents (other than vaccines) and because the prevention of COVID-19 is shifting to a more personalized, patient-specific approach, the complexity of clinical decision-making has increased. Additionally, patients may face barriers in obtaining COVID-19 prevention. In this activity, based on a recent live symposium, expert faculty and a patient advocate discuss strategies to improve the uptake of COVID-19 prevention and increase patient and clinician engagement and how to develop a plan to customize COVID-19 prevention at point of care for patients needing prevention. In addition, they look at creating strategies for patients in order to help in overcoming real-time barriers. Upon completion of this activity, participants should be better able to: Improve the uptake of COVID-19 prevention and increase patient and clinician engagement in following science-based evidence; Develop a plan to customize COVID-19 prevention at point of care for patients needing protection against the virus using evidence-based recommendations and guidelines; and Facilitate patient access to needed COVID-19 prevention by creating strategies to overcome real-time barriers.
Go online to PeerView.com/MKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is an increasingly prevalent, chronic, T2 inflammatory disease triggered by food and/or environmental allergens. Due to underlying tissue inflammation, patients suffer diminished quality of life due to symptoms such as weight loss, difficulty swallowing, and heartburn. Patients can experience these symptoms for a long time before receiving a proper diagnosis. Once diagnosed, treatment options have historically been limited. Fortunately, therapies that treat other type 2 disorders are in development or are approved to treat EoE. At a recent live event, experts used patient cases to discuss the diagnosis, underlying causes, and the newest treatments for EoE, including biologic therapies. Watch this on-demand version now! Upon completion of this activity, participants should be better able to: Distinguish signs and symptoms of eosinophilic esophagitis (EoE) among children and adults to enable an earlier diagnosis and minimize complications due to uncontrolled disease; Recognize underlying mechanisms of EoE, including the role of key cytokines such as interleukins -4, -13, and -5 as drivers of type 2 inflammation and how this relates to emerging treatment; and Apply the latest expert recommendations and clinical evidence to the treatment of patients with EoE, particularly as novel and emerging agents become available.
Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.
Go online to PeerView.com/JPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further integration of different antibody-based approaches into patient management. How can professionals exploit these advances while using the principles of shared decision-making when caring for patients? In this activity, two hematologist-oncologists and a patient advocate explore these themes through a case-based discussion of novel antibody platforms in a range of MM treatment settings. Learners can expect insights on the safety and efficacy evidence supporting the use of antibody-based therapies in newly diagnosed and relapsed MM, along with practical guidance for safe delivery of care, and strategies for engaging with patients when developing treatment plans that include antibody components. Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations surrounding the use of novel antibody platforms in multiple myeloma (MM); Integrate established and emerging antibody options, including monoclonal and bispecific antibodies, into treatment plans for patients with MM based on guideline recommendations and the latest clinical data; Address practical aspects of antibody therapy in MM, including unique safety considerations and effective sequential treatment; and Counsel patients with MM on dosing, safety, drug delivery, and therapeutic expectations with novel antibodies when engaging in shared decision-making discussions.
Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.
Go online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy. Upon completion of this activity, participants should be better able to: Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM); Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM; and Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting.
Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.
Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.
Go online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL. Upon completion of this activity, participants should be better able to: Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs; Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations; and Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care.
Go online to PeerView.com/SDX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The arrival of immunotherapy in basal cell carcinoma (BCC) increases the potential for successful treatment outcomes—are you prepared to address several practical questions related to selection and sequencing of immunotherapy, safety management, and patient monitoring? In this activity, based on a recent PeerView Live Seminars & Tumor Board educational event held at the 2022 American Society of Clinical Oncology Annual Meeting, our expert panel links the evidence supporting the use of immunotherapy in locally advanced and metastatic BCC with case-based teaching designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards, ultimately illustrating how checkpoint inhibitors can be integrated into the care of patients with BCC. Leverage the power of immunotherapy to improve clinical outcomes for your patients with advanced BCC! Upon completion of this activity, participants should be better able to: Cite the rationale, therapeutic role, and current evidence and guidelines supporting the use of immune checkpoint inhibitors (ICIs) in the management of advanced BCC; Integrate novel immunotherapy options into the management of appropriate patients with advanced BCC in consultation with the wider management team; and Employ proactive, team-based approaches to recognize, mitigate, and manage potential immune-related adverse events in patients receiving ICI therapy for advanced BCC.
Go online to PeerView.com/EWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Solid organ transplant recipients may be at increased risk for COVID-19 because they are immunosuppressed and less likely to mount effective immune responses to vaccination. In this educational symposium based on a live event, a panel of expert faculty address the identification of transplant patients who would likely derive benefit from anti-SARS-CoV-2 monoclonal antibodies (mAbs) and strategies that can be used to overcome barriers to COVID-19 pre-exposure prophylaxis access. In addition, they provide guidance on mAb qualities and clinical profiles and shared decision-making strategies to customize mAb pre-exposure prophylaxis at the point of care for transplant recipients needing protection against COVID-19. After participating in this activity, the learner will demonstrate the ability to: Identify post-transplant patients who would likely derive benefit from pre-exposure prophylaxis with anti-SARS-CoV-2 monoclonal antibodies (mAbs); Use strategies to overcome barriers to COVID-19 pre-exposure prophylaxis access for post-transplant patients; and Incorporate evidence-based recommendations and guidelines, mAb qualities and clinical profiles, and shared decision-making into strategies to customize mAb pre-exposure prophylaxis at point of care for post-transplant patients needing protection against COVID-19.
Go online to PeerView.com/YEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In collaboration with HealthTree Foundation, this “Seminars and Tumor Board” program makes new developments in multiple myeloma (MM) care comprehensible by focusing on how the “myelennial” tool kit can be leveraged for different patient populations and in different treatment settings. Using a series of case-based sessions, our expert panelists provide instruction on the use of next-generation triplets and quadruplets, maintenance strategies, and effective therapeutics in early relapse and treatment-refractory disease. Link cutting-edge evidence in MM to clinical decisions in your own practice—watch today! Upon completion of this activity, participants should be better able to: Cite current practice recommendations and clinical evidence surrounding the efficacy of novel proteasome inhibitor and IMiD options, novel antibody platforms, targeted agents, and cellular therapy across MM treatment settings; Select personalized, evidence-based regimens with novel components for the management of patients with newly diagnosed MM according to baseline comorbidities, functional status, and patient preferences, among other factors; Select evidence-based treatment plans for relapsed/refractory MM that integrate novel antibody, targeted, and CAR-T options into patient care; and Manage the unique toxicities associated with innovative therapeutics in patients with MM, including cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome.
Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
Go online to PeerView.com/KQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The use of asparaginase, including E coli- and Erwinia-derived compounds, remains an important component of pediatric acute lymphoblastic leukemia (ALL) care, and its use has consistently improved survival outcomes—are you up to the challenge of developing modern regimens that ensure appropriate exposure to asparaginase? In this PeerView CME activity, based on a live “Clinical Consults” symposium at the 2022 ASPHO conference, Drs. Stuart S. Winter and Reuven Schore address the challenges of clinical decision-making with asparaginase compounds as part of pediatric ALL therapy, focusing on topics such as the management of E coli-derived asparaginase hypersensitivity or silent inactivation, preventing discontinuation/truncation, and the integration of novel Erwinia formulations when E coli-derived asparaginase discontinuation occurs. Tune in to learn how to adapt your practice to reflect the innovative science supporting the use of modern asparaginase compounds in pediatric ALL. Upon completion of this activity, participants should be better able to: Describe the clinical ramifications of Escherichia coli asparaginase hypersensitivity and asparaginase discontinuation in pediatric acute lymphoblastic leukemia (ALL), Cite efficacy and safety evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations as a component of multi-agent chemotherapy for pediatric ALL, Implement strategies to overcome barriers to the effective use of asparaginase in pediatric ALL, including the use of appropriate monitoring and management for hypersensitivity, mitigation for infusion reactions, and the integration of novel Erwinia asparaginase compounds into treatment plans.
Go online to PeerView.com/GBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS)—a serious complication arising in the aftermath of hematopoietic stem cell transplantation? In addition to life-threatening organ dysfunction in serious cases, VOD presents additional diagnostic and assessment challenges based on its varied onset time and symptomatology. PeerView’s Clinical Consults CME video will help you meet these challenges head-on through a series of case-centric lectures illustrating how modern VOD management techniques can improve outcomes in adult and pediatric patients at risk for this post-transplant complication. Throughout, our expert panelists will highlight the modern tools and evidence that can help capture VOD cases, determine the presence of organ dysfunction, and support the initiation of timely supportive care and pharmacologic treatment. Upon completion of this activity, participants should be better able to: Describe risk factors for VOD/SOS, updated diagnostic criteria, and clinical markers of disease severity/multiorgan failure, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including for individuals presenting with or without organ dysfunction, Use modern severity grading models to determine the presence of organ dysfunction in patients with a VOD/SOS diagnosis, Incorporate novel therapies into treatment plans for VOD/SOS, including in the setting of multiorgan dysfunction, based on clinical assessment and current evidence.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient’s baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/KPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell co-stimulation blocking agent abatacept, as well as additional novel strategies being tested in a range of acute and chronic GVHD settings. In this activity from the 2022 Tandem meetings, our expert panelists distill the current evidence on novel therapeutics in the prevention and treatment of GVHD; throughout, they illustrate how and when to integrate novel therapeutics into care, provide guidance on how to prepare for emerging strategies, and offer practical takeaways on the changing nature of GVHD management. Upon completion of this activity, participants should be better able to: Discuss current evidence supporting the use of novel therapeutics as prophylactic or treatment options for acute or chronic graft-versus-host disease (GVHD) in the post-transplant setting, including JAK and BTK inhibitors, T-cell blocking agents, α1-antitrypsin, and ROCK inhibitors, among others, Develop management plans informed by evidence and practice guidelines that incorporate novel therapeutics into the management of acute GVHD, Integrate novel and emerging therapies into management plans for the management of chronic GVHD, including novel combinatorial strategies and/or options for second-line management.
Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.
Go online to PeerView.com/FSQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in asthma discusses the role of airway hyper-responsiveness in severe uncontrolled asthma. Upon completion of this activity, participants should be better able to: Compare the pathophysiology of airway inflammation with airway hyper-responsiveness (AHR) and their clinical manifestations in patients with severe asthma, Apply insights with regard to the role of AHR, as well as recent clinical evidence concerning the efficacy of biologic agents in addressing AHR, to the management of patients with severe asthma.
Go online to PeerView.com/DTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules symmetrically distributed on the trunk and extremities. PN is defined by intense pruritus lasting ≥6 weeks, history of repeated scratching, and subsequent development of pruritic, elevated, firm, and nodular skin lesions, in a vicious itch–scratch cycle. The intense itch associated with PN leads to sleep disturbances and reduced social participation and work productivity, resulting in a drastically reduced quality of life and psychosocial disturbances. Unfortunately, these issues experienced among patients with PN are further compounded by the lack of effective treatment options. In this activity, based on a recent live educational symposium, a panel of experts addresses real-world questions and dilemmas faced by providers and the PN patients for whom they care. By providing practical guidance on how to effectively integrate the latest evidence and expert recommendations into real-world clinical scenarios, this activity provides participating clinicians with the necessary tools to effectively navigate the rapidly changing landscape for PN. Additionally, patient videos are utilized throughout to convey key information regarding the burden of PN and optimal management strategies. Upon completion of this activity, participants should be better able to: Discuss the impact on quality of life and economic implications of prurigo nodularis (PN), Describe the pathophysiology of PN as it relates to clinically relevant disease mechanisms and novel therapeutic targets, Evaluate emerging treatment options for PN in the context of mechanism of action, efficacy, and safety, Treat PN in accordance with current evidence and expert recommendations, recognizing that an effective treatment approach should be based on clinical judgment and tailored to the individual needs of the patient.
Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient’s clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.
Go online to PeerView.com/VMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss assessing and managing uncontrolled, moderate to severe asthma for pediatric and adult patients, as well as selecting targeted therapies and improving treatment adherence. Upon completion of this activity, participants should be better able to: Assess the severity of asthma in pediatric and adult patients according to evidence-based practice guidelines, Identify patients that would likely benefit from targeted therapy, considering the relationship between type 2 inflammation, moderate to severe asthma, and comorbid conditions such as atopic dermatitis, Select treatment for pediatric and adult patients with uncontrolled, moderate to severe asthma according to current evidence and guidelines, Use techniques to educate and communicate more effectively with patients and caregivers to better engage them in their care, and improve adherence to individualized treatment plans.
Go online to PeerView.com/DRJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to bring modern approaches to the treatment of patients with biliary cancers to your clinical practice? Learn how the treatment paradigm is shifting from conventional chemotherapy to biomarker-guided treatments and immunotherapy in a new event from PeerView and the Cholangiocarcinoma Foundation. Our experts will offer learners a deep dive into the latest science on the biologic rationale for targeting prevalent genetic aberrations in biliary cancers and review key safety and efficacy data from recent pivotal clinical trials of novel strategies. Through discussions of relevant patient scenarios, our panel will offer insight on how to integrate biomarker-guided treatments into clinical practice and practical guidance on identifying patients with advanced biliary cancers who are eligible for targeted treatment. Upon completion of this CE activity, participants will be able to: Summarize the rationale for use and recent efficacy and safety data on newly available and emerging therapeutic strategies for patients with advanced biliary cancers, including FGFR, IDH, TRK, multikinase, HER2, and immune checkpoint inhibitors, Identify patients with advanced biliary cancers who are eligible for treatments with available and emerging therapies targeting FGFR genomic aberrations, multikinase tumor pathways, HER2 alterations, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Integrate the latest clinical evidence into the management of patients with advanced biliary cancers, utilizing molecular testing and established and emerging targeted options based on individual tumor characteristics in the context of clinical practice or a clinical trial.
Go online to PeerView.com/FTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma detail the pathophysiology of severe asthma, with a discussion of the underlying mechanisms behind both type 2 and non–type 2 asthma, and novel and emerging therapies for its treatment. Upon completion of this CE activity, participants will be able to: Discuss unmet treatment needs for patients with severe, uncontrolled asthma, particularly those who lack an eosinophilic or allergic phenotype, Explain the role of thymic stromal lymphopoietin (TSLP) as a driver of eosinophilic, allergic, and neutrophilic inflammation as well as structural changes to the airway in asthma due to its position at the top of the inflammatory cascade, Recognize the potential of targeted therapies that block the activity of epithelial cytokines such as TSLP for the treatment of severe, uncontrolled asthma, Identify patients who might be eligible for treatment with novel/emerging biologic therapies that target epithelial cytokines such as TSLP.
Go online to PeerView.com/WUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the practice-changing evidence supporting the use of immunotherapy in resectable melanoma? In this activity, a panel of surgical and medical oncology experts will guide you through these new developments and provide insights on the real-world use of immunotherapy in resectable melanoma, including expanded applications of immunotherapy. The panelists will tackle topics such as the use of checkpoint inhibitors as standard adjuvant therapy in stage III/IV melanoma; the potential of adjuvant immunotherapy in stage II disease; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging novel immune-based treatments in resectable melanoma (eg, LAG-3 inhibitors). This program will help inform the identification of optimal candidates for immunotherapy, address treatment selection and dosing considerations, and support effective management of immune-related events. Upon completion of this CE activity, participants will be able to: Summarize updated evidence and guideline recommendations supporting the use of adjuvant and neoadjuvant immunotherapy in resectable or potentially resectable melanoma, including in stage II, III, and IV settings, Select appropriate adjuvant immunotherapy options for patients with resected melanoma requiring additional treatment, including those with BRAF-mutant and wild-type disease, Integrate neoadjuvant immunotherapy into the management of patients with melanoma who may benefit from presurgical treatment, Manage immune-related adverse events in patients with melanoma receiving immunotherapy in conjunction with surgery.
Go online to PeerView.com/DMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hypereosinophilic syndrome discusses the burden, symptoms, and differential diagnosis of the disease, as well as the latest data on treatment. Upon completion of this CE activity, participants will be able to: Describe the burden of hypereosinophilic syndrome (HES) on patients, including the consequences of underdiagnosed and undertreated HES, Explain the role of eosinophils in the pathophysiology of HES, Identify features of HES that differentiate the diagnosis from other eosinophilic disorders, Develop treatment plans for patients with HES based on subtype and the latest clinical evidence.
Go online to PeerView.com/FTS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity has been designed to meet the educational needs of gastroenterologists (pediatric and adult), allergists/immunologists (pediatric and adult), nurses, NPs, PAs, and other clinicians involved in the management of EoE. Upon completion of this CE activity, participants will be able to: Distinguish signs and symptoms of eosinophilic esophagitis (EoE) among children and adults to enable an earlier diagnosis and minimize complications due to uncontrolled disease, Summarize underlying mechanisms of EoE, including the role of key cytokines such as interleukin-4, -13, and -5 as drivers of type 2 inflammation and how this relates to potential treatment, Review the limitations of the current standard of care for the treatment of EoE, Apply the latest expert recommendations and clinical evidence to the treatment of patients with EoE, particularly as novel and emerging agents become available.
Go online to PeerView.com/AYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts will review the presentation and diagnosis of AD and discuss the current evidence and guidelines for treatment selection for pediatric and adult patients. The faculty will also offer their thoughts on engaging with patients to provide personalized care and improved outcomes. Learn from the data and the experts in this informative, engaging discussion. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD), Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines, Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care.
Go online to PeerView.com/SQH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in eosinophilic esophagitis discuss the diagnosis of pediatric and adult EoE, the current standard of care, and novel and emerging treatments that may be the future of EoE management. Upon completion of this CE activity, participants will be able to: Differentiate signs and symptoms of eosinophilic esophagitis (EoE) among children and adults to facilitate early diagnosis and minimize complications caused by uncontrolled disease, Describe the underlying pathophysiology of EoE and how it correlates to potential treatment targets such as interleukin-4, -13, and -5, Discuss the limitations of the current standard of care for the treatment of EoE, Apply the latest clinical evidence to the treatment of patients with EoE, particularly as novel and emerging agents become available.
Go online to PeerView.com/KHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an allergy expert discusses the mechanism of action and current treatment approaches for managing IgE-mediated food allergies. Upon completion of this accredited CE activity, participants should be better able to: Discuss key limitations associated with current treatment approaches for managing food allergies, Differentiate the mechanisms of action of current and emerging treatments for IgE-mediated food allergies, Identify patients with IgE-mediated food allergies who would likely derive benefit from treatment with IgE-blocking therapies.
Go online to PeerView.com/AZH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in eosinophilic esophagitis discusses the latest research, data, and guidelines on novel and emerging targeted therapies. Upon completion of this CE activity, participants will be able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of eosinophilic esophagitis (EoE), Employ the latest clinical data, including evidence concerning novel and emerging targeted therapies, into treatment plans for the management of patients with EoE as they become available.
Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.
Go online to PeerView.com/RSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children. Upon completion of this accredited CE activity, participants should be better able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of pediatric and adult patients with moderate to severe atopic dermatitis, Apply the latest clinical evidence on approved and emerging biologic therapies into personalized treatment plans for pediatric and adult patients with moderate to severe atopic dermatitis.
Go online to PeerView.com/BQR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live satellite symposium held at HFSA 2021, expert faculty review the evidence for current and emerging treatment strategies for hypertrophic cardiomyopathy (HCM) using patient cases to illustrate the ways in which clinicians can adapt current practices and utilize shared decision-making to offer appropriate treatment options to patients with HCM. Upon completion of this activity, participants should be better able to: Recognize HCM’s pathophysiology and the associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Apply the latest recommendations and guidance for diagnosing, evaluating, and monitoring patients with HCM in a team-based manner, Evaluate current and emerging strategies for managing HCM in terms of efficacy, safety, and effects on burden of disease, Collaborate with patients to identify their individual goals and counsel them about the benefits and risks of testing and treatment.
Go online to PeerView.com/DWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pulmonology discusses the latest clinical research and treatment guidelines on approved biologic therapies for the management of adult and pediatric patients with uncontrolled moderate to severe asthma. Upon completion of this accredited CE activity, participants should be better able to: Explain to peers the latest developments in clinical research and treatment guidelines with regard to the use of currently approved targeted therapy for the management of adult and pediatric patients with uncontrolled moderate to severe asthma, Integrate recent clinical research findings on approved biologic therapies into personalized treatment plans for adult and pediatric patients with uncontrolled moderate to severe asthma.
Go online to PeerView.com/PGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in blood and marrow transplantation illuminate the roles of various members of the transplant team in the overall approach to diagnosing and treating VOD/SOS, while also offering learners a window into how hematologist-oncologists, transplant specialists, advanced practice clinicians, radiologists, pathologists, nurses, pharmacists, and other team members can collaborate to overcome the many challenges of VOD/SOS. Upon completion of this activity, participants should be better able to: Explain the clinical signs, symptoms, and medical burden of VOD/SOS to patients preparing for transplantation, Apply team-based approaches to risk assessment and diagnostic confirmation of VOD/SOS, including interpretation of clinical symptoms/disease onset and use of techniques such as ultrasound imaging or other strategies as appropriate, Use modern adverse event severity grading models to determine the presence and severity of organ dysfunction in patients with a VOD/SOS diagnosis, Recommend appropriate team management options for adult and pediatric patients with VOD/SOS in the post-HCT setting.
Go online to PeerView.com/GZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two melanoma experts engage in case-based discussions and scientific lecture segments on topics such as the selection of immunotherapy in metastatic disease, best practices for the use of adjuvant or neoadjuvant checkpoint blockade, and how future care will be defined by emerging science on novel immunotherapy combination approaches. Upon completion of this accredited CE activity, participants should be better able to: Cite current evidence and guideline recommendations for the use of immunotherapy in resectable stage III/IV melanoma and unresectable, metastatic disease, Summarize evidence on novel applications of immunotherapy in melanoma, including as neoadjuvant therapy, as an adjuvant option for stage II disease, or as part of novel combinatorial approaches, Integrate immunotherapy into the management of patients with resectable and unresectable melanoma, including those with BRAF-positive or BRAF-negative disease, Manage immune-related adverse events in patients with melanoma receiving immunotherapy across the spectrum of disease.
Go online to PeerView.com/FXM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses the latest evidence on novel cytokine-modulating strategies in the treatment of moderate to severe psoriasis. Upon completion of this accredited CE activity, participants should be better able to: Recognize unmet needs in the treatment of moderate to severe psoriasis, Describe the pathophysiology of psoriasis, recognizing current and emerging targets for therapeutic intervention, Summarize efficacy and safety data related to nonbiologic oral therapies and novel cytokine inhibitors for the treatment of moderate to severe psoriasis, Treat moderate to severe psoriasis in accordance with current evidence and individual patient needs, identifying those who would likely derive benefit from novel therapeutic options.
Go online to PeerView.com/NJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses unmet needs of patients with moderate to severe psoriasis and the clinical potential of targeting the TYK2 pathway as a novel nonbiologic oral therapeutic option. Upon completion of this accredited CE activity, participants should be better able to: Explain the role of the JAK-STAT signaling pathway in the pathophysiology of psoriasis, Summarize efficacy and safety data related to current and emerging kinase inhibitors for the treatment of psoriasis, Treat moderate to severe psoriasis in accordance with current evidence and guidelines, recognizing the role of nonbiologic therapies in addressing the burden of disease and comorbidities in individual patients.
Go online to PeerView.com/NZQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy currently has a role as consolidation therapy after chemoradiation for patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). Other agents and strategies are being explored in the locally advanced setting as well. Many clinical trials are also investigating the use of immune checkpoint inhibitors as neoadjuvant and adjuvant systemic therapies in earlier stages of NSCLC, and promising data have started to emerge, including from the first few phase 3 studies. With the continual expansion of immunotherapy into earlier disease settings, multidisciplinary collaboration among thoracic surgeons, medical oncologists, radiation oncologists, and the greater lung cancer care team is paramount. This PeerView Live Seminar and Practicum based on a recent live web broadcast explores the latest advances and clinical trial findings with immunotherapies, analyzes implications for surgical management of patients, and provides case-based, practical guidance for integrating immunotherapies into multimodal management of stage I-III NSCLC in the context of multidisciplinary care. Upon completion of this accredited CE activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Determine the best treatment approaches for patients with stage III or earlier lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.
Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/HKY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option. Upon completion of this activity, participants should be better able to: Recognize AHP and associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Describe evidence-based interventions for AHP, including the rationale and trial data for recently approved siRNA therapy, Apply evidence-based diagnostic and treatment approaches to minimize disease impact and burden for individuals with AHP.
Go online to PeerView.com/KQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of patients with non–small cell lung cancer (NSCLC) is exemplary of precision medicine. Extensive and nuanced genomic profiling of NSCLC is essential to inform individualized treatment plans to optimize patient outcomes. Currently, there are seven different molecular alterations for which FDA-approved targeted therapies are available: EGFR, ALK, ROS1, BRAF V600E, NTRK, MET exon 14, and RET. With the growing complexity of the targeted therapeutic landscape of lung cancer, it is imperative that members of the multidisciplinary care team maintain best practices regarding genomic testing to effectively incorporate targeted therapies into clinical practice. This PeerView educational activity based on a recent web broadcast provides practical guidance for navigating the continuing wave of predictive genomic alterations and related matched therapies, uniting pathologists with oncologists and other multidisciplinary specialists to ensure that patients with genomically altered NSCLC receive appropriate testing and therapy. Upon completion of this activity, participants should be better able to: Discuss the expanding role and increasing importance of broad molecular testing for identifying patients with NSCLC who have therapeutically targetable molecular alterations, Describe the molecular alterations that are clinically relevant and therapeutically targetable in NSCLC, and the latest testing methods for identifying these alterations, Analyze data from clinical trials of precision therapies that target key molecular alterations in NSCLC, Implement best practices and collaborative strategies for integration of wide-spread molecular testing to ensure that patients with NSCLC receive the most appropriate therapies in the context of clinical practice or clinical trials.
Go online to PeerView.com/BFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC/CC/NCPD-accredited activity, a hematologist-oncologist, a pathologist, and a physician assistant team up to discuss a collaborative approach to managing their patients with high-risk myeloid cancers, such as acute myeloid leukemia and myelodysplastic syndrome. Hear how Naval Daver, MD, Sanam Loghavi, MD, and Megan Wiese, PA-C, from the MD Anderson Cancer Center, collaborate on diagnosis, treatment decision-making, safety management, and patient education, with the ultimate goal of providing the best care for their patients. Upon completion of this activity, participants will be able to: Discuss the clinical signs and diagnostic principles of high-risk myeloid cancers, including TP53-mutant disease, Summarize current evidence related to the efficacy and safety of novel strategies for the management of high-risk acute myeloid leukemia or myelodysplastic syndromes, Develop team-based diagnostic, treatment, and safety management plans for patients presenting with high-risk myeloid cancers, Apply team-based educational interventions detailing prognostic and therapeutic expectations for patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.
Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
Go online to PeerView.com/SDN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nephrology discusses evidence-based strategies to individualize immunosuppressive therapy and optimize long-term outcomes after renal transplantation. Upon completion of this activity, participants should be better able to: Identify risk factors for graft loss and mortality after renal transplantation, Recognize the benefits and limitations of current immunosuppressive strategies used to prevent acute rejection and promote long-term graft survival after renal transplantation, Apply evidence-based approaches to optimize maintenance immunosuppressive therapy in individual kidney transplant recipients, recognizing how and when to initiate CNI-sparing strategies, Describe emerging strategies to prolong the durability of transplanted kidneys as well as potentially improve long-term outcomes for kidney transplant patients.
Go online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon completion of this activity, participants should be better able to: Describe current guidelines for transplant eligibility and the use of novel therapeutics as induction, pretransplant conditioning, or post-HCT maintenance for AML, Discuss safety and efficacy evidence related to innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Select evidence-based regimens with novel components for use in conjunction with allogeneic HCT in the AML setting.
Go online to PeerView.com/MME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelofibrosis (MF) is a rare myeloproliferative neoplasm which can lead to marrow fibrosis, neo-angiogenesis, and osteosclerosis causing progressive splenomegaly with or without hepatomegaly. Currently, the only potential cure for MF is hematopoietic cell transplantation (HCT). However, the emergence and validation of JAK inhibitors has impacted treatment decisions, including the timing of HCT, and newer evidence suggests that next-generation JAK inhibitors may also play a role in challenging treatment settings defined by failure of upfront JAK inhibitor therapy. Clinicians therefore should be prepared to develop truly personalized, newer therapeutic strategies for MF management that consider all available options—from targeted agents to supportive care, as well as HCT—and address the role of JAK inhibitors in patients who are transplant candidates and determine their role before and, possibly, after transplantation. In this activity based on a recent live web broadcast, a panel of experts describes the current therapeutic landscape of MF, including JAK inhibitors and HCT. They also review evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in MF. Upon completion of this activity, participants should be better able to: Describe modern diagnostic and prognostic models, as well as molecular and clinical features that are useful for capturing myelofibrosis (MF) presentations, including primary MF and post-PV/ET MF, Review the current therapeutic role of JAK inhibitors and allogeneic hematopoietic cell transplantation (HCT), including reduced-intensity transplant, in the management of MF, Cite recent safety and efficacy evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in the management of MF, Integrate modern JAK inhibitor-based regimens into risk-adapted treatment plans for patients with symptomatic MF, including those who are eligible for allogeneic transplantation or as sequential options in the non-HCT setting.
Go online to PeerView.com/ERM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps (CRS/NP) discusses how to diagnose and manage CRS/NP; identifies patients with severe, inadequately controlled CRS/NP to determine eligibility for targeted biologic therapy; and discusses treatment plans for patients with CRS/NP according to international consensus statements and the latest clinical evidence as part of a multidisciplinary approach. Upon completion of this activity, participants should be better able to: Describe the burden that chronic rhinosinusitis with nasal polyps (CRS/NP), including certain treatment measures, such as surgery, may have on patient quality of life, Identify patients with severe, inadequately controlled CRS/NP to determine eligibility for targeted biologic therapy, Develop treatment plans for patients with CRS/NP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.
Go online to PeerView.com/CAV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the benefits and limitations of available immune checkpoint inhibitors, investigational immunotherapies, and rational combinations that may expand the therapeutic landscape for various malignancies, and explains how to integrate the latest immunotherapy approaches into cancer care in the context of clinical practice or ongoing studies. Upon completion of this activity, participants should be better able to: Summarize the benefits and limitations of available immune checkpoint inhibitors and the need for novel immunotherapies and combinations to optimize outcomes for patients with cancer, Discuss investigational immunotherapies and rational combinations that may be able to expand on the current therapies or overcome immune evasion and resistance, Integrate the latest immunotherapy approaches into cancer care in the context of clinical practice or clinical trials.
Go online to PeerView.com/MSE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is an aggressive form of lung cancer that lacked treatment advances for more than three decades. Fortunately, immune checkpoint inhibitors have recently revolutionized the extensive-stage (ES) SCLC treatment landscape, and combination chemoimmunotherapy has become the new standard of care in the first-line setting. Research efforts are continuing to refine and expand the role of immunotherapies in SCLC. To make the most of this novel therapeutic approach, it is essential for oncology professionals as well as the broader multidisciplinary team of professionals to keep up with the latest therapeutic advances and collaborate effectively to establish the diagnosis, ensure a rapid initiation of therapy, and appropriately manage potential immune-related adverse events. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. Leading experts provide an engaging educational session on the latest science, best practices, and multidisciplinary implications related to integrating cancer immunotherapies into the management plans for patients with ES-SCLC. Upon completion of this activity, participants will be able to: Describe the epidemiology, clinical features, and current treatment of extensive-stage small cell lung cancer (ES-SCLC), including immunotherapies that can improve long-term outcomes, Examine the latest efficacy, safety, and biomarker data from clinical trials evaluating available and emerging immunotherapies and immune-based combinations for ES-SCLC, Implement optimal strategies for screening, diagnosing, and staging of patients with lung cancer to ensure timely and accurate diagnosis, prompt oncology referral, and rapid treatment initiation for patients with ES-SCLC, Apply best practices for collaboration and coordination of care with oncologists and other members of the multidisciplinary lung cancer team to provide optimal care to patients with ES-SCLC, including the integration of immunotherapies into treatment plans and recognition/management of irAEs, and improve outcomes.
Go online to PeerView.com/ATX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new multiple myeloma (MM) CME program, two leading myeloma experts discuss key questions and controversies arising from the rapid validation of novel therapeutics for patients with MM who are autologous stem cell transplantation (ASCT) eligible. Although the use of ASCT remains a core therapeutic modality for MM, using ASCT in conjunction with innovative treatment options—including CAR-T cell therapy, proteasome inhibitors, immunomodulators, and antibodies such as, CD38 antibodies, BCMA-targeting antibody-drug conjugates, and bispecific antibodies—can substantially improve outcomes. These improvements have been observed across the continuum of care, from primary therapy to the management of relapsed/refractory disease (post-ASCT), as well as in the setting of minimal residual disease eradication. Hear our expert panel as they highlight these improvements and discuss the integration of approved and emerging novel therapies in MM. Upon completion of this activity, participants should be better able to: List current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in various multiple myeloma treatment settings, Describe efficacy and safety data surrounding novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new targeted agent classes in the management of ASCT-eligible patients with multiple myeloma, Develop regimens with novel components for ASCT-eligible patients with multiple myeloma, including as induction/consolidation or maintenance therapy, or in the setting of early relapse or refractory myeloma.
Go online to PeerView.com/QUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel of hematologists, oncologists, and a patient advocate discuss compelling, real-world case scenarios and the practice-changing evidence that continues to support the increasing role of novel therapeutics in CLL. This event also explores the future of CLL care and illustrates how novel combinations and cellular therapy may lead to deep, durable, and minimal residual disease-negative responses. Upon completion of this activity, participants should be better able to: Cite genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence and practice guideline recommendations related to the use of novel therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel components for patients with treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with the use of novel therapies in patients with CLL, Educate patients with CLL about treatment expectations, unique toxicity profiles, and dosing/adherence considerations with novel therapeutics.
Go online to PeerView.com/FSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As precision medicine has taken a varying course in the setting of hematologic cancers, safely integrating effective, novel therapeutics into the management of patients whose cancers express markers such as CD30 and CD123 is more important than ever. In this activity, our experts discuss the diagnostic and treatment implications of these markers in various hematologic disease settings and use workshop-style educational segments with patient cases and clinical scenarios to illustrate the medical benefits of precision medicine for hematologic cancers defined by CD30 and CD123 expressions. Upon completion of this activity, participants should be better able to: Describe the significance of CD30 and CD123 in a range of hematologic cancers, including implications for diagnosis, immunophenotypic/molecular testing, and prognosis, Cite current efficacy and safety evidence on the use of novel therapeutics in CD30-expressing lymphoma, including in patients with newly diagnosed or relapsed disease, Discuss current evidence on the use of CD123-targeting agents in a range of hematologic cancers characterized by CD123 expression, Integrate novel therapeutics into the management of patients with newly diagnosed or relapsed/refractory Hodgkin or T-cell lymphoma, blastic plasmacytoid dendritic cell neoplasm, and chronic myelomonocytic leukemia, Manage safety considerations associated with the use of novel therapeutics in patients with CD30- or CD123-expressing malignancies.
Go online to PeerView.com/XNY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps discusses novel and emerging biologic therapies to improve the quality of life for patients with chronic rhinosinusitis with nasal polyps. Upon completion of this activity, participants should be better able to: Recognize the burden that chronic rhinosinusitis with nasal polyps (CRS/NP) on patient quality of life, Describe the pathophysiology of CRS/NP and its relevance to novel therapeutic targets, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRS/NP, Apply individualized treatment plans, including the use of targeted biologic therapy, for patients with CRS/NP inadequately controlled on standard therapy.
Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton’s tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.
Go online to PeerView.com/VAY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss the most recent clinical evidence supporting modern antibody options in acute lymphoblastic leukemia (ALL), explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Upon completion of this activity, participants should be better able to: Discuss current practice guidelines illustrating the role of antibody therapy in the management of newly diagnosed or relapsed/refractory ALL, including in Ph-negative or -positive disease, as a pretransplant strategy, or in patients with residual disease, Cite current evidence surrounding innovative antibody-based approaches, including antibody–drug conjugates and bispecific antibodies, in the management of ALL, Select evidence-based regimens with antibody components for the management of patients with ALL, Manage safety considerations related to the use of antibody therapy in patients with Ph-negative or -positive ALL.
Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.
Go online to PeerView.com/KGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses the relationship between type 2 inflammation and moderate to severe asthma and the use of targeted biologic therapies as treatment. Upon completion of this activity, participants should be better able to: Explain the relationship between type 2 inflammation and moderate-to-severe asthma, biomarkers such as blood eosinophils, and other comorbid conditions, Identify patients with uncontrolled moderate-to-severe asthma who are eligible for targeted biologic therapies based on clinical characteristics of type 2 inflammation, Develop treatment plans for patients with uncontrolled moderate-to-severe asthma according to updated evidence-based guidelines and the latest clinical data on efficacy and safety regarding targeted biologic therapy.
Go online to PeerView.com/DKK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystemic disorder that can be fatal if left untreated. EGPA is characterized by moderate-to-severe asthma, peripheral blood eosinophilia, mononeuropathy or polyneuropathy, pulmonary infiltrates, paranasal sinus abnormalities, and extravascular eosinophils or eosinophilic vasculitis. Optimal treatment involves accurate diagnosis of the condition, keeping abreast of novel and emerging therapies, and a multidisciplinary approach. This web broadcast features two experts in EGPA as they aim to give a greater understanding into the recognition, diagnosis, and individualized management of EGPA. The event concludes with a practicum discussion to connect the data with real-life application. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of eosinophilic granulomatosis with polyangiitis (EGPA) and its relationship to novel therapeutic targets, Recognize the importance of a multidisciplinary approach in diagnosing and managing patients with EGPA, Apply evidence-based approaches to diagnose and differentiate EGPA from other eosinophilic disorders, Develop individualized treatment plans for patients with EGPA based on the latest clinical data.
Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.
Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient’s genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.
Go online to PeerView.com/QBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC-accredited video activity, Josep Tabernero, MD, PhD, gives his perspective on the latest evidence on novel HER2-targeted and other molecular-directed therapies in gastric cancer. Hear about recent data presented on gastric cancer and how precision medicine may improve gastric cancer patient care. Upon completion of this activity, participants should be better able to: Review the biologic rationale for targeting molecular signatures of gastric cancer, such as HER2 or PD-L1 overexpression, Examine expert and guideline-based biomarker testing recommendations in gastric cancer that can guide optimal treatment selection, Assess the latest safety and efficacy evidence of novel therapeutics for gastric cancer, such as checkpoint inhibitors, cytotoxic agents, and HER2-directed antibody-drug conjugates, Develop safe and effective validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.
Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.
Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers. This onDemand activity based on a recent live PeerView Virtual Seminar and Workshop provides pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, an expert panel reviews evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.
Go online to PeerView.com/BYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity Professor David I. Marks, Farhad Ravandi, MD, and Matthias Stelljes, MD, give insights on the evidence behind the emergence of antibody therapy and its use in conjunction with HSCT in AML and ALL. These scientific MasterClass sessions are paired with a case-centered segment that illustrates therapeutic nuances such as the identification of transplant-eligible patients who may benefit from antibody-enhanced treatment protocols and the management of safety considerations unique to the use of antibodies in HSCT populations. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction/consolidation, pretransplant conditioning, or other roles in conjunction with transplant in the acute leukemia setting, Summarize updated evidence surrounding innovative antibody-based approaches to induction/consolidation, conditioning, or post-HSCT therapy in patients with AML or ALL, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HSCT for patients with AML or ALL, Manage safety considerations related to the use of antibody therapy in transplant-eligible populations with acute leukemia.
Go online to PeerView.com/GKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapies are addressing a big unmet need in triple-negative breast cancer (TNBC) due to limited treatment options, the aggressive nature of the disease, and poor patient outcomes. This PeerView Live MasterClass and Practicum provides a comprehensive overview of the evolving role of immune checkpoint inhibitors in TNBC, specifically directed to surgeons. Experts explain the biologic rationale for the use of cancer immunotherapies in TNBC and explore the clinical evidence supporting their use in advanced/metastatic TNBC, as well as neoadjuvant/adjuvant settings of early-stage TNBC. Additionally, the faculty provides guidance on the practicalities of patient/tumor evaluation and candidate selection for immunotherapies, including their use in the context of other treatment modalities, and detection and management of immune-related adverse events. Strategies for effective collaboration and coordination of care among surgeons, oncologists, and other specialists in the era of immuno-oncology are also shared. Upon completion of this activity, participants should be better able to: Review the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC), including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies that may enhance immunogenicity and improve outcomes, Evaluate the efficacy, safety, biomarker, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including early-stage (neoadjuvant/adjuvant settings) and advanced/metastatic disease, Integrate immunotherapies into treatment plans for patients with TNBC based on the latest evidence, indications, recommendations, disease stage/treatment setting, patient and tumor characteristics, and other relevant factors in the context of effective multidisciplinary collaboration.
Go online to PeerView.com/YHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME video activity, experts in systemic lupus erythematosus (SLE) give a detailed discussion on the autoimmune disease, providing guidance on recognizing the clinical features and confirming a diagnosis, as well as contemporary strategies to manage diverse disease manifestations. Hear what the experts are doing in their clinics. Upon completion of this activity, participants should be better able to: Identify systemic lupus erythematosus (SLE) as a heterogeneous autoimmune disease with a wide range of clinical and serological manifestations that can affect any organ, Employ appropriate criteria to confirm a diagnosis of SLE, recognizing the clinical utility of available classification systems, Utilize evidence-based tools to monitor disease activity in individual SLE patients in daily clinical practice and guide treatment decisions, Describe current treatment options for SLE according to mechanism of action, efficacy, safety, and impact on patient symptoms/quality of life, Develop treatment plans for individual patients with SLE to control disease activity and prevent or minimize disease flares, drug toxicity, and organ damage, Effectively communicate and collaborate with SLE patients and other care providers to understand and address the needs of each patient and maximize treatment adherence, quality of life, and survival outcomes.
Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.
Go online to PeerView.com/PHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of triple-negative breast cancer (TNBC) has remained challenging for many years, with limited effective options and poor outcomes for most patients. But the tide is turning, as new therapies are emerging for this patient population, with immunotherapy representing a new pillar of care in the treatment of TNBC. TNBC is known to be more immunogenic compared with other breast cancer subtypes, and thus, immunotherapy has been and continues to be extensively explored in TNBC. Clinical trials have started to show promising results in both advanced and early-stage TNBC; the first combination of an immune checkpoint inhibitor and chemotherapy has been approved by the FDA for the first-line treatment of PD-L1+ TNBC, and it is likely that the treatment landscape will continue to expand. In this educational on-demand activity based on a recent live web broadcast, a panel of leading experts discusses the current and emerging roles of immunotherapy in TNBC as well as the clinical trial data assessing immunotherapies and immune-based combinations throughout the continuum of TNBC. The practical nuances of patient selection, treatment integration, biomarker testing, and immune-related adverse event management are also explored. Upon completion of this activity, participants should be better able to: Discuss the rationale for use of cancer immunotherapies in the treatment of triple-negative breast cancer (TNBC) specifically and breast cancer more broadly, Assess efficacy, safety, and other key data from clinical trials assessing immunotherapies and immune-based combinations throughout the continuum of TNBC, including in metastatic settings as well as in early-stage disease in neoadjuvant or adjuvant settings, and relevant implications for clinical practice, Evaluate the current and emerging role of immunotherapies in TNBC, nuances of patient selection and treatment integration, biomarker testing when relevant, management of immune-related adverse events, and other practical aspects related to their use in clinical practice, Integrate immune checkpoint inhibitors into treatment plans of patients with TNBC based on latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, and patient needs/preferences.
Go online to PeerView.com/KFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Dr. Heather McArthur provides a brief recap of how the emergence of checkpoint inhibitor therapy in TNBC has changed the management of this challenging subtype of breast cancer, and what some of the unanswered questions and controversies are that ongoing research is aiming to answer. Upon completion of this activity, participants should be better able to: Discuss the rationale for use of cancer immunotherapies in the treatment of triple-negative breast cancer (TNBC) specifically and breast cancer more broadly, Assess efficacy, safety, and other key data from clinical trials assessing immunotherapies and immune-based combinations throughout the continuum of TNBC, including in metastatic settings as well as in early-stage disease in neoadjuvant or adjuvant settings, and relevant implications for clinical practice, Evaluate the current and emerging role of immunotherapies in TNBC, nuances of patient selection and treatment integration, biomarker testing when relevant, management of immune-related adverse events, and other practical aspects related to their use in clinical practice, Integrate immune checkpoint inhibitors into treatment plans of patients with TNBC based on latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, and patient needs/preferences.
Go online to PeerView.com/RXX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pulmonology discusses key issues in the diagnosis and treatment of patients with uncontrolled persistent asthma. Several case vignettes provide insights on assessing phenotype/endotype and eligibility for biologic therapy in these patients, in the context of common comorbidities and other patient-, disease-, and treatment-related factors. Upon completion of this activity, participants should be better able to: Describe the role of the type 2 inflammatory cascade in uncontrolled persistent asthma and the implications for treatment, Evaluate patients with asthma for symptom severity, phenotype/endotype, exacerbation risk, and eligibility for biologic therapies, Employ the latest clinical data on efficacy and safety of biologic therapies to the treatment of patients with uncontrolled persistent asthma, Use strategies to engage patients in shared decision-making to improve outcomes and quality of life.
Go online to PeerView.com/VBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity, Josep Tabernero, MD, PhD; Geoffrey Ku, MD; and Kohei Shitara, MD, synthesize the latest data of emerging and available novel therapies and consider the future of gastric cancer care. These experts also examine best practices for testing biomarkers such as HER2, PD-L1, and MSI, and provide guidance on integrating scientific advances and novel therapeutics into sound, evidence-based management strategies to improve outcomes for patients with gastric cancer. Upon completion of this activity, participants should be better able to: Review the biologic rationale for targeting molecular signatures of gastric cancer, such as HER2 or PD-L1 overexpression, Examine expert and guideline-based biomarker testing recommendations in gastric cancer that can guide optimal treatment selection, Assess the latest safety and efficacy evidence of novel therapeutics for gastric cancer, such as checkpoint inhibitors, cytotoxic agents, and HER2-directed antibody-drug conjugates, Develop safe and effective validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.
Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.
Go online to PeerView.com/FDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CNE activity, a family nurse practitioner brings the nurse’s perspective to patient care in endometrial and cervical cancer. Kimberly Halla, MSN, FNP-C, discusses modern management techniques for patient’s receiving targeted therapy and immunotherapy, as well as combination therapies, and gives her take on how to approach the unique safety profiles associated with these treatment options. Upon completion of this activity, participants will be able to: Summarize the current treatment and regulatory landscape in the management of gynecologic cancers, including the role of novel targeted, immunotherapeutic, and combination approaches in cervical and endometrial cancers, Describe safety and efficacy evidence surrounding targeted, immune checkpoint inhibitor, and combination strategies for the management of gynecologic cancers, Educate patients about therapeutic and safety considerations associated with recently approved and emerging options for endometrial and cervical cancers, Manage the unique spectrum of adverse events associated with targeted and immunotherapy used to treat endometrial and cervical cancers.
Go online to PeerView.com/WHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The evidence base for use of immunotherapy in lung cancer is expanding at a rapid pace, and immune checkpoint inhibition has become a new standard of care after chemoradiation in stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). The effectiveness of immunotherapy as a component of multimodal therapy has raised the possibility of further expanding this treatment approach to earlier stages of lung cancer, including as neoadjuvant or adjuvant therapy for patients with resectable disease. A range of novel single-agent and combination immunotherapeutic approaches are being explored, and results are eagerly anticipated. However, many challenges and questions related to the optimal use of immunotherapies in earlier stages of lung cancer remain. For example, which patients are most likely to benefit from immune-based therapies? What is the optimal way to individualize therapy and coordinate care among different specialists, including thoracic surgeons, radiation oncologists, and medical oncologists? How should the various adverse effects associated with these emerging treatment modalities be managed? This educational on-demand activity based on a recent live webcast features expert instruction and practical guidance for how to effectively navigate the rapidly changing and complex immunotherapy landscape in lung cancer, including in earlier disease settings as a component of multimodal therapy. Access the activity to learn more about this timely, important topic, and what the implications are for clinical practice. Upon completion of this activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Determine the best treatment approaches for patients with stage III or earlier stages of lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.
Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.
Go online to PeerView.com/KAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hematology discusses the recognition, classification, and treatment of adult and pediatric patients with veno-occlusive disease and sinusoidal obstruction syndrome. Upon completion of this activity, participants should be better able to: Cite updated recommendations and evidence on veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) risk factors, diagnostic criteria, and disease severity grading, Establish a diagnosis of VOD/SOS, including late-onset disease, and VOD/SOS with or without organ dysfunction in adult and pediatric populations, Recommend effective, timely treatment for patients with confirmed VOD/SOS, including those presenting with or without organ dysfunction.
Go online to PeerView.com/TYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Brendon Stiles, MD, provides a brief recap of the latest advances in the use of immunotherapy as a component of multimodal lung cancer care in locally advanced and earlier stages of NSCLC. He highlights some of the newest data from clinical trials and shares his perspective on the promise and implications of the transition of immune checkpoint inhibitor therapy into curative intent settings of lung cancer. Upon completion of this activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Determine the best treatment approaches for patients with stage III or earlier stages of lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.
Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.
Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients’ needs.
Go online to PeerView.com/KNT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the basic biology of how the immune system responds to tumor activity, reviews the pathophysiology of the tumor microenvironment, provides up-to-date data supporting the use of cancer immunotherapies, including immune checkpoint inhibitors, and discusses investigational immuno-oncology pathways, putative targets for novel therapies, and current and emerging prognostic biomarkers to inform clinical treatment decisions. Upon completion of this activity, participants will be able to: Describe the foundational aspects of the immune system’s response to tumor activity through innate and adaptive immunity mechanisms, Review the pathophysiology of the tumor microenvironment and its relationship to tumor evasion and resistance, Characterize the mechanisms of action of the immune checkpoint inhibitors (ie, CTLA-4 and PD-1/PD-L1 inhibitors) and how they differ in their activity and adverse effects from conventional anticancer therapies, Summarize the current FDA-approved indications and investigational approaches with the immune checkpoint inhibitors across different tumors, Discuss investigational immuno-oncology pathways and potential new therapies that may be able to expand on the current therapies or overcome immune evasion and resistance, Assess current and emerging immuno-oncology biomarkers and their potential roles/uses, Integrate the latest immunotherapies and biomarker approaches into cancer care in the context of clinical practice or trials.
Go online to PeerView.com/BBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert discusses key concepts in oncology and supportive care biosimilars, including how they are defined, the regulatory approval process for these agents, and an overview of data for biosimilars in the treatment and supportive care of cancer patients. Upon completion of this activity, participants will be able to: Describe the biosimilar manufacturing process and differences between biosimilars and originator biologics used in the oncology setting, Discuss the concepts of biosimilar interchangeability, therapeutic equivalence, and safety in the context of the regulatory process, Cite efficacy evidence on the use of biosimilars in the management of solid tumors, including breast cancer, lung cancer, GI cancers, and others, Integrate biosimilars into oncology management plans in order to increase patient access to effective medications and improve health system efficiency.
Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma, Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma, Recommend optimized induction and post-ASCT maintenance/consolidation regimens for eligible patients with multiple myeloma, Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease.
Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.
Go online to PeerView.com/GVC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses how to effectively diagnose and assess atopic dermatitis, common comorbidities, international treatment guidelines, and optimal treatment strategies, including phosphodiesterase-4 and interleukin-4/-13 inhibitors. Upon completion of this activity, participants should be better able to: Recognize the multidimensional burden and unmet needs associated with atopic dermatitis (AD), Employ evidence-based strategies to determine disease impact and guide treatment decisions in individual patients with AD, Assess clinical data on new and emerging treatment options for atopic dermatitis, Develop individualized treatment plans for adults, adolescents, and children with atopic dermatitis based on current recommendations, the safety and efficacy of new and emerging treatment options, comorbidities, and patient quality of life.
Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.
Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.
Go online to PeerView.com/MYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts on severe asthma discuss how to identify and diagnose patients with this condition and how novel treatments are improving patient outcomes. A patient joins the discussion to share his unique experience with severe asthma and how biologic therapy has improved his quality of life. Upon completion of this activity, participants should be better able to: Diagnose and evaluate patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapy, Employ evidence-based guidelines and the latest clinical data when selecting treatment for patients with severe asthma, Use strategies to communicate effectively with patients about self-management and to improve inhaler technique, adherence, and overall quality of life in patients with severe asthma.
Go online to PeerView.com/UQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts in the management of myelofibrosis (MF) offers learners an update on the modern diagnostic and risk assessment strategies that have informed a more considered treatment approach to symptomatic disease. An emerging paradigm, in which potentially curative hematopoietic cell transplantation (HCT) is used in conjunction with Janus kinase (JAK) inhibitor therapy, is discussed, along with an expert-led assessment of JAK inhibitor options in development for MF and how these additions to the treatment arsenal will be used alongside standard approaches. For professionals who are looking to pair recent evidence on JAK inhibitors with HCT and other options in the management of MF, this educational event is an essential disease management resource. Upon completion of this activity, participants should be better able to: Identify clinical symptoms and molecular/mutational features that can be used to diagnose and risk-stratify myelofibrosis, Discuss the current treatment role of JAK inhibitors and allogeneic transplantation in the management of myelofibrosis, Cite recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of myelofibrosis, Develop risk-adapted treatment plans for patients with symptomatic myelofibrosis, including those who did not respond to previous JAK inhibitor therapy or are eligible for allogeneic transplantation.
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
Go online to PeerView.com/SGN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an eosinophilic granulomatosis with polyangiitis (EGPA) expert offers expert insight to help physicians achieve a greater understanding into the recognition, diagnosis, and management of EGPA, including the latest clinical evidence with respect to novel and emerging therapies. Upon completion of this activity, participants should be better able to: Review the pathophysiology of EGPA and its correlation to the discovery of novel therapeutic targets, Use evidence-based criteria to diagnose and differentiate EGPA from other eosinophilic disorders, Select therapies for patients with EGPA based on the latest clinical data as part of an individualized treatment plan, Discuss the importance of the multidisciplinary team in the management of patients with EGPA
Go online to PeerView.com/WUA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an oncology nurse practitioner and expert in immuno-oncology provides a comprehensive overview of cancer immunotherapies, including how the immune checkpoint inhibitors work, their efficacy and safety profiles, and the latest approvals and indications. In addition, practical guidance for determining candidates for immune checkpoint inhibitor therapy, recognizing and managing immune-related adverse effects, and educating and counseling patients and survivors about this new class of agents and what to expect during and after treatment is offered. Upon completion of this activity, participants will be able to: Assess clinical data on the efficacy and safety of cancer immunotherapies and immune-based combinations across the oncologic spectrum, Describe indications for and roles of immunotherapies and combinations in the treatment of different cancers, Discuss factors that should be considered in determining best candidates for cancer immunotherapies, including patient-related factors and predictive biomarkers, Characterize potential immune-related adverse effects (irAEs) of cancer immunotherapies and how to recognize, diagnose, and manage them, Evaluate patients with cancer to help determine who would/would not be good candidates for cancer immunotherapy, Manage irAEs according to the latest recommendations and best practices, Educate patients with cancer and survivors about the basics of immuno-oncology, what to expect during and after treatment with cancer immunotherapies, and how they can collaborate with their nurses, nurse navigators, other members of the oncology team, and other providers to maximize the benefits and minimize the risks of these therapies
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
Go online to PeerView.com/KWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment armamentarium for advanced renal cell carcinoma (RCC) has undergone rapid expansion with the validation of novel multitargeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. More recently, the emergence of dual checkpoint blockade and immunotherapy-TKI combinations in RCC has increased the number of treatment choices in the frontline setting, allowed for greater flexibility when selecting second-line agents, and sparked additional research into TKI and immune checkpoint inhibitor options in earlier disease settings. In the wake of these advances, understanding how to effectively select and sequence newer regimens through multiple lines of therapy while ensuring safe usage is crucial to maximize beneficial patient outcomes throughout the advanced RCC continuum. This unique “How I Think, How I Treat” educational on-demand activity, based on an event held adjunct to the 18th International Kidney Cancer Symposium, features personal insights from leading kidney cancer experts on how they are adapting their own practice based on the evidence supporting optimized care in advanced RCC in the context of patient-, disease-, and treatment-specific factors, as well as how the innovations fueling modern approaches to care are improving outcomes for patients with RCC. Upon completion of this activity, participants should be better able to: Assess the latest evidence and clinical implications of novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Apply validated targeted therapy and immunotherapy options effectively for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC
Go online to PeerView.com/FKM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the therapeutic landscape of several lymphoid cancers, including chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). The present and future management of these diseases will increasingly be defined by the integration of BTK inhibitors—along with other novel therapeutics—into management protocols that have previously been characterized by the use of immunochemotherapy-focused options. Several important practical issues arising from the use of BTK inhibitors, ranging from the initial therapy selection to therapeutic sequencing and use of active combinations, will continue to be a part of patient management for years to come. This PeerView Live “How I Think, How I Treat” on-demand activity, based on a satellite symposium preceding the 61st ASH Annual Meeting and Exposition, exposes learners to the personal insights of several experts in the field and includes in-depth analyses of the cutting-edge science on the present and future role of BTK inhibitors in CLL, MCL, and other lymphoid cancers. Key topics include BTK inhibitor sequencing, selecting patients for treatment, differentiating among first- and second-generation compounds, and safety management. Ultimately, this event provides a “virtual mentorship” experience on the use of BTK inhibitors in several different diseases. Upon completion of this activity, participants should be better able to: Describe updated evidence regarding the use of first- and second-generation BTK inhibitors in the management of B-cell NHL, including agent potency/selectivity, response data, survival outcomes, and activity in BTK inhibitor–intolerant or –resistant disease, Recommend personalized therapy with BTK inhibitors for patients across the spectrum of B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, among others, Manage unique safety considerations associated with BTK inhibitor therapy in patients with B-cell NHL
Go online to PeerView.com/JYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity an expert in acute and chronic graft-versus-host disease (GVHD) discusses the underlying biologic features of GVHD and the latest evidence supporting the use of innovative therapeutics in this setting. The expert also provides guidance on clinical and practical experience with current treatment options for acute and chronic, previously untreated, and steroid-refractory GVHD, while also discussing new data and ongoing clinical trials in GVHD prophylaxis. Upon completion of this activity, participants should be better able to: Describe the underlying immunology of post-transplant GVHD, and the rationale for and mechanisms of novel therapies in the management of GVHD, Discuss the latest evidence on innovative therapies for management of acute or chronic, steroid-refractory GVHD, Apply the most optimal evidence-based strategies, including recently approved and investigational therapies in the context of clinical trials, for post-transplant GVHD care based on individual patient and disease characteristics
Go online to PeerView.com/PMD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tremendous advances have been made in the treatment of many other subtypes of breast cancer, but treatment of triple-negative breast cancer (TNBC) has remained challenging. However, recent developments suggest that we are on the brink of a new era in TNBC therapy that will bring the novel class of cancer immunotherapies to this population of patients. What is the most rational way and optimal setting to use cancer immunotherapies? How can we maximize their benefits so that more patients with TNBC would benefit from them? In this CME/MOC/CNE-accredited PeerView MasterClass on-demand activity, our expert panel discusses the biologic rationale for the use of cancer immunotherapies in breast cancer in general and TNBC specifically, as well as evolving evidence supporting the use of immune checkpoint inhibitors in advanced/metastatic and early-stage TNBC in neoadjuvant and adjuvant settings. Additionally, the panel focuses on patient/tumor evaluation and candidate selection for immunotherapies, using current and novel biomarkers to guide clinical decisions in early-stage and advanced disease, the importance of being aware of potential immune-related adverse events and how to diagnose/manage them, and the need for close collaboration among oncologists, breast surgeons, pathologists, and other professionals involved in the management of patients with breast cancer. Illustrative case studies and clinical scenarios discussed during the Practicum segment provide further guidance on best practices for the use and integration of immunotherapies into the treatment arsenal for patients with TNBC in real-world, clinical practice settings. Upon completion of this activity, participants will be able to: Describe the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC) specifically, and in breast cancer more broadly, including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies (eg, chemotherapies, other immunotherapies, PARP inhibitors and other targeted agents, surgery, radiation, etc) that may enhance immunogenicity and improve outcomes, Discuss biomarkers that may have utility in guiding and refining clinical decisions regarding the selection of appropriate candidates for immune-based and other therapies in TNBC, and the nuances of testing for these biomarkers in practice, Analyze efficacy, safety, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including metastatic, locally advanced, and early-stage resectable disease, Integrate immune checkpoint inhibitors and/or other effective treatment modalities into management plans of patients with TNBC based on the latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, biomarker testing results, and patient needs/preferences
Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP
Go online to PeerView.com/EPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses advances in the understanding of the pathogenesis of asthma and novel targeted treatments that have been developed as a result. Strategies for identifying uncontrolled moderate-to-severe asthma patients who would benefit from these agents and clinical data for the currently available and emerging biologic therapies for asthma treatment are also discussed. Upon completion of this activity, participants should be better able to: Describe the economic impact and quality-of-life burden of moderate-to-severe asthma, Discuss the inflammatory mediators and mechanisms that provide the basis for the phenotypes and endotypes of severe asthma and their relevance to novel biologic therapies, Assess the latest clinical data with regard to efficacy and safety for currently available and emerging biologic therapies for the treatment of severe asthma, Apply treatment for patients with asthma based on symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies
Go online to PeerView.com/GWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Tumor Board video activity, based on an educational session from The Liver Meeting® (American Association for the Study of Liver Diseases) in Boston, features a panel of hepatology, oncology, surgery, and interventional radiology experts, who provide their clinical perspectives on cutting-edge science that has validated, newly available systemic treatment options in HCC. Coupled with each MasterClass, the Tumor Board segments feature reflective case-centered discussions on the crucial role that hepatology clinicians serve across the HCC continuum of care. Upon completion of this activity, participants should be better able to: Evaluate the safety and efficacy data of multikinase and checkpoint inhibitors and antiangiogenic therapy indicated for advanced HCC, Summarize emerging clinical evidence on the use of novel systemic options in conjunction with or as an alternative to continued LRT for patients with intermediate HCC, Implement multidisciplinary team-based approaches to develop safe, personalized treatment algorithms that utilize novel components for patients with HCC
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
Go online to PeerView.com/FWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in pulmonology discuss strategies for overcoming challenges in the management of severe asthma and the role of targeted therapies in personalized care. Upon completion of this activity, participants should be better able to: Explain the role of inflammatory mediators and mechanisms in the pathogenesis of severe asthma and in the context of treatment targets, Summarize the latest clinical data related to efficacy and safety for currently available and emerging treatments for severe asthma, Create treatment plans for patients with severe asthma based on the latest guidelines and efficacy and safety data, disease severity, phenotype/endotype, and patient preferences, Employ patient education and communication strategies to improve inhaler technique, patient adherence, self-management, and overall quality of life in patients with severe asthma
Go online to PeerView.com/YAX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of chronic obstructive pulmonary disease (COPD) begins with accurate diagnosis and ongoing, appropriate assessment of disease severity. The burden of COPD, and its associated morbidity and mortality, are not always recognized, and underdiagnosis remains prevalent. A personalized, evidence-based approach to the management of patients with COPD, including the selection of treatment based on various factors such as patient symptomatology, comorbidities, exacerbation risk, choice of inhalation device, and phenotypic characteristics, can help healthcare providers in guiding their patients down a path to successful treatment. Proper technique and adherence, as well as involving the patient in the creation of a COPD action plan and goal setting, so they may better manage COPD in their everyday life, are also key elements in a patient’s journey with COPD. In this activity, our expert panel explores the use of evidence-based guidelines in diagnosing patients and the therapeutic role of eosinophils. In addition, the panel discusses the creation of treatment plans, proper inhaler technique, and the importance of adherence for patients with COPD. Upon completion of this activity, participants should be better able to: Employ evidence-based guidelines to accurately diagnose and monitor patients with chronic obstructive pulmonary disease (COPD), Discuss the potential role of eosinophils in selecting maintenance therapy for patients with COPD, Create maintenance treatment plans for patients with COPD, based on factors including efficacy, safety, patient symptomatology, comorbidities, and exacerbation risk, Apply strategies to ensure proper inhaler use and encourage goal setting and medication adherence for patients with COPD
Go online to PeerView.com/WGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies to optimize the care of patients with chronic spontaneous urticaria in the primary care setting. Upon completion of this activity, participants should be better able to: Recognize the clinical presentation of chronic spontaneous urticaria and its impact on patient quality of life, Employ evidence-based guidelines to accurately diagnose patients with chronic spontaneous urticaria, Apply therapeutic options for treating chronic spontaneous urticaria in the context of available evidence and current treatment algorithms, Assess key data sets on the efficacy and safety of emerging pharmacologic treatments for chronic spontaneous urticaria
Go online to PeerView.com/XHY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology and pediatric primary care discuss the management of patients with atopic dermatitis. A patient also joins the discussion to provide unique perspectives on living with atopic dermatitis and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Diagnose atopic dermatitis in individual patients based on recognition of clinical manifestations and application of current diagnostic criteria and guidelines, Describe the mechanisms of action and clinical profiles of new and emerging topical and systemic therapies for atopic dermatitis, Select appropriate treatments for patients with atopic dermatitis based on current guideline recommendations, the safety and efficacy of available treatment options, comorbidities, and burden of disease, Employ shared decision-making approaches to create individualized treatment plans for atopic dermatitis, Implement patient/caregiver education strategies to improve adherence to atopic dermatitis treatment (eg, managing application-site pain associated with topical therapies) and assess the effects of treatment on patient quality of life
Go online to PeerView.com/ZVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematologist/oncologist and a nurse professional discuss the characteristics and management of secondary AML, with an emphasis on practical aspects of care and the use of novel therapy. This multidisciplinary panel also features commentary from a patient with secondary AML and discusses the patient’s experience of a secondary AML diagnosis and subsequent therapeutic journey. Upon completion of this activity, participants should be better able to: Cite the clinical features and therapeutic challenges associated with secondary AML, Recommend novel treatment strategies for patients with secondary AML who are able to receive intensive therapy and/or are eligible for HCT, Identify opportunities for multidisciplinary collaboration with other oncology team members when managing secondary AML, Educate patients about the risks and benefits of novel treatment strategies for secondary AML in the context of a collaborative oncology team.
Go online to PeerView.com/TXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the management of MM discusses the implications of recent efficacy and safety data that support the ongoing integration and use of several innovative treatments, such as antibody-based therapies, next-generation IMiDs and proteasome inhibitors, and novel therapies directed against intracellular targets. The expert also provides a review of the overall shape of MM therapy in newly diagnosed and relapsed disease, and discusses strategies to manage treatment-related adverse effects. Upon completion of this activity, participants will be able to: Summarize updated evidence on the use of novel agent classes and next-generation therapeutics in multiple myeloma (MM), including proteasome inhibitors, immunomodulators (IMiDs), novel antibodies, and targeted agents, Select appropriate therapy in patients with newly diagnosed MM, including those requiring eradication of MRD or treatment for high-risk disease, Recommend therapy with novel components for patients with early relapse or treatment-refractory MM, Manage treatment-related adverse events in patients with MM who are receiving novel therapeutics as part of their care.
Go online to PeerView.com/WED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non–small cell lung cancer (NSCLC) is one of the tumor types where the novel class of cancer immunotherapies—the immune checkpoint inhibitors—has had the biggest impact and certainly become a major component of the treatment arsenal in the advanced disease setting. While the approval and availability of an increasing number and variety of immunotherapeutic agents and combinatorial options has been welcomed by clinicians and patients alike, clinical decision-making has also become quite complicated. How to identify the right candidates for immunotherapy? What biomarkers should be tested to guide candidate selection? And which agent or combination to use for individual patients? All these questions and more are explored in this engaging and entertaining educational session based on a live symposium held adjunct to the 2019 American Society of Clinical Oncology Annual Meeting (ASCO 2019). Modeled after the format of a late-night talk show, this activity merges focused talks on defined topics with personal story-telling, candid interviews, and interactive debates/discussions among top experts. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies and combinations in the frontline setting and beyond in advanced/metastatic NSCLC, Assess the role of predictive biomarkers (PD-L1, TMB) and other tumor-, patient-, and treatment-related factors that should be taken into consideration as part of individualized treatment planning and selection for patients with NSCLC, Describe key new research directions and clinical trials with immunotherapies aiming to refine, expand, and maximize their use throughout the lung cancer continuum, including novel immune targets or combinations and biomarkers in advanced settings, as well as potentially curative approaches in earlier stages of NSCLC, Implement individualized, evidence-based, patient-centric treatment plans involving immunotherapies and/or combinations for patients with NSCLC.
Go online to PeerView.com/XEJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple new drug approvals and positive clinical trial outcomes have set the stage for the wider integration of novel therapeutics across the treatment spectrum of hepatocellular carcinoma (HCC). These developments have established multiple targeted and immunotherapy agents as options in advanced disease while also mapping potential future applications in intermediate stage HCC and beyond. Future care will depend on the successful integration of newer tyrosine kinase inhibitor (TKI)-based approaches with established and emerging immune checkpoint inhibitors across patient populations and lines of therapy. This PeerView “How I Think, How I Treat” activity, based on a symposium held during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, offers an inside look at how experts translate important new data and navigate the current HCC landscape in order to provide the most benefit for their patients. This activity also features important insights on how to utilize newly approved TKIs and checkpoint inhibitors across disease and treatment settings, as well as provides expert thoughts on the next wave of emerging solutions that leverage the power of novel therapies across the continuum of HCC. Upon completion of this activity, participants should be better able to: Summarize emerging clinical evidence on the use of novel systemic treatments, including targeted and immunotherapeutic agents, in a range of HCC treatment settings and populations, Apply recent safety and efficacy data on targeted therapies into clinical practice to enhance aspects of HCC care, including treatment sequencing and managing treatment-related adverse events, Integrate immunotherapeutic strategies for the management of patients with advanced HCC, including through optimal treatment selection and via management of immune-related adverse events, Identify innovative treatment strategies currently being assessed in clinical trials across the spectrum of HCC, such as immunotherapy combinations, combinations of novel agents with locoregional therapies, and early transition to systemic treatment, among others.
Go online to PeerView.com/PBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss recent advances in the treatment of uncontrolled persistent asthma and offer practical guidance on personalizing patient care. Upon completion of this activity, participants should be better able to: Describe the mechanisms of inflammatory pathways in uncontrolled persistent asthma and their implications for treatment, Assess patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies, Apply evidence-based guidelines and the latest clinical data when selecting treatment for patients with uncontrolled persistent asthma, Implement patient education and communication tactics in personalized treatment plans to improve patient adherence, self-management, and quality of life.
Go online to PeerView.com/TVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology reviews recent evidence for novel therapeutics for the management of mantle cell lymphoma and offers practical insight on integrating clinical evidence into patient care and management, including for patients who have progressed after upfront therapy and who are candidates for second-line treatment. Upon completion of this activity, participants should be better able to: Cite evidence on the use of newer therapeutics, including BTK inhibitors and immunomodulators, among others, for the management of relapsed/refractory and newly diagnosed MCL, Select regimens with novel components for the management of patients with MCL, Manage therapy-related toxicity in patients with MCL who are receiving treatment with novel therapeutics.
Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.
Go online to PeerView.com/FPP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, recorded from a live event at the 2019 American Society of Clinical Oncology Annual Meeting, a panel of kidney cancer experts offers case-centric discussion of key evidence that supports clinical decision-making through multiple lines of therapy in advanced RCC, as well as practical instruction on how to effectively and safely integrate novel targeted and immunotherapeutic strategies in an increasingly complex RCC treatment landscape. Upon completion of this activity, participants should be better able to: Summarize the latest evidence and ongoing investigations with novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies, in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Recommend targeted agents and immune checkpoint inhibitors optimally to patients with pretreated advanced RCC through multiple lines of therapy, with considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC.
Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.
Go online to PeerView.com/GSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses the latest evidence and data on treatment for persistent asthma presented at the American Thoracic Society Conference 2019 in Dallas, Texas. Upon completion of this activity, participants should be better able to: Discuss the latest clinical data for the efficacy and safety of approved and emerging treatments for uncontrolled persistent asthma, Employ strategies to treat patients with uncontrolled persistent asthma in the context of late-breaking data and patient-, disease-, and therapy-related factors.
Go online to PeerView.com/XFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Already a cornerstone of care for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), immune checkpoint inhibitors are being explored in earlier treatment settings and in combination with other pillars of SCCHN care (such as surgery and radiotherapy). In this MasterClass activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 ASCO Annual Meeting, experts in head and neck (HNC) explore the evidence that is redefining the role of immunotherapy in HNC and offer insight on applications of new evidence on immunotherapy in HNC, as well as its future as a part of multimodal treatment plans. This activity also features a dedicated “Tumor Board” session designed to provide useful guidance on integrating checkpoint inhibitors into care—from the selection of upfront immunotherapy to the role of clinical trials as options for patients eligible for immune treatment. Upon completion of this activity, participants will be able to: Summarize evidence on the use of immune checkpoint inhibitors as single agents or in combination with other strategies in recurrent/metastatic, locally advanced, or resectable squamous cell carcinoma of the head and neck, Integrate immune checkpoint inhibitors into the treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck, including as upfront treatment or after progression on platinum chemotherapy, Identify patients with head and neck cancer who are eligible to receive immunotherapy as part of multimodal care across the disease spectrum, including in the context of a clinical trial, Manage immune-related adverse events in patients with squamous cell carcinoma of the head and neck receiving immunotherapy as single agents or in combination with other treatment modalities.
Go online to PeerView.com/EHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Several disease-modifying therapies (DMTs) are now approved for MS management, and a number of emerging therapies are under investigation for the treatment of this disease. In this unique PeerView Talks activity, based on a live symposium held at the 2019 CMSC Annual Meeting, leading experts engage in a live discussion of current data on available and investigational therapies for the treatment of MS, as well as how to personalize DMT selection. The faculty share their personal experiences and the “Stories Behind the Science” that connect the evidence to real-world clinical practice. Upon completion of this activity, participants will be able to: Apply available data on approved disease-modifying therapies when managing patients with multiple sclerosis, Identify recent data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of multiple sclerosis, Cite current data on potential markers that may correlate with disease activity and severity and treatment response, Select an optimal course of disease-modifying therapy for individuals with MS according to their level of disease activity, preferences, and other factors.
Go online to PeerView.com/TGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in venous thromboembolism (VTE) reviews the latest clinical science and guidelines pertaining to cancer-associated VTE prophylaxis and treatment. This video-based program also focuses on strategies to help learners prepare for the practical integration of direct oral anticoagulants (DOACs) in cancer-associated VTE and illustrates how this development can lead to clinical improvements in the prevention and management of VTE in the cancer setting. Upon completion of this activity, participants will be able to: Use established clinical tools to assess the risk for VTE in patients preparing to receive anticancer therapy, Summarize current evidence and guidelines on VTE treatment and prophylaxis including the use of direct oral anticoagulation in patients with cancer, Apply updated evidence on the use of DOACs as initial VTE therapy and/or thromboprophylaxis in the cancer setting.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/CPZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New evidence from clinical trials assessing immunotherapies and combinations in lung cancer is emerging at a rapid pace. As a result, the treatment landscape is constantly evolving, and checkpoint inhibitor–based therapeutic approaches are establishing a foothold not only in advanced disease but in earlier stages of lung cancer as well. Immunotherapy has proven to be effective in the context of multimodal therapy in stage III locally advanced NSCLC. This has increased excitement about further expanding the role of this therapeutic approach in earlier stages of lung cancer, including resectable disease. A range of novel single-agent and combination immunotherapeutic approaches are being explored in studies in different settings and populations throughout the disease continuum, and the results are eagerly anticipated. However, many challenges and questions related to the optimal use of immunotherapy in stage III and earlier stages of lung cancer remain. In this activity, based on a recent satellite symposium, an expert panel of two surgeons and a medical oncologist offers practical guidance on how to navigate the rapidly changing and complex immuno-oncology landscape in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Review the present immunotherapy landscape and state of the science in lung cancer, including key approvals/indications in different settings from early-stage to more advanced disease, Discuss key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, including resectable disease, and available data from such trials, Determine the best treatment approaches for patients with stage III or earlier lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.
Go online to PeerView.com/ZEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tremendous advances have been made in the treatment of many other subtypes of breast cancer, but treatment of triple-negative breast cancer (TNBC) has remained challenging. However, recent developments suggest that we are on the brink of a new era in TNBC therapy that now brings the novel class of cancer immunotherapies to this population of patients. In this activity, based on a recent live satellite symposium held in Dallas, Texas during the 20th Annual Meeting of The American Society of Breast Surgeons, our expert panel discusses the biologic rationale for the use of cancer immunotherapies in breast cancer in general and TNBC specifically, as well as the evolving evidence supporting the use of immune checkpoint inhibitors in advanced/metastatic and early-stage resectable TNBC. Additionally, the panel focuses on patient/tumor evaluation and candidate selection for immunotherapy, using current and novel biomarkers to guide clinical decisions in early-stage and advanced disease, the importance of being aware of potential immune-related adverse events and how to diagnose/manage them, and the need for close collaboration among breast surgeons, oncologists, pathologists, and other professionals involved in the management of patients with breast cancer. Upon completion of this activity, participants will be able to: Describe the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC) specifically, and in breast cancer more broadly, including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies (eg, chemotherapies, other immunotherapies, PARP inhibitors and other targeted agents, surgery, radiation, etc.) that may enhance immunogenicity and improve outcomes, Discuss biomarkers that may have utility in guiding and refining clinical decisions regarding the selection of appropriate candidates for immune-based and other therapies in TNBC, and the nuances of testing for these biomarkers in practice, Analyze efficacy, safety, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including metastatic, locally advanced, and early-stage resectable disease, Integrate immune checkpoint inhibitors and/or other effective treatment modalities into management plans of patients with TNBC based on the latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, biomarker testing results, and patient needs/preferences.
Go online to PeerView.com/UXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss various treatment options for small cell lung cancer (SCLC), including the rationale for using new therapies, key clinical trial data, and methods for integrating novel therapies into routine practice or through clinical trial participation. Upon completion of this activity, participants will be able to: Describe the mechanisms of action and rationale for use of novel therapies for SCLC, including immune checkpoint inhibitors, PARP inhibitors, transcription inhibitors, and other investigational agents and combinations, Discuss key clinical trials assessing different new therapies for SCLC, Evaluate the latest available clinical trial data regarding standard as well as novel/emerging therapeutic approaches for SCLC, Integrate novel therapies into treatment plans for patients with SCLC either in the context of routine clinical practice or clinical trial participation.
Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.
Go online to PeerView.com/FJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and the presence of DNA mismatch repair deficiencies (dMMR) or high levels of microsatellite instability (MSI-H) should presently be routinely done in oncology and pathology practice in alignment with the latest recommendations and indications. Assessment of tumor mutational burden (TMB) is also showing great promise as a new and distinct predictor of benefit from cancer immunotherapies. Other novel biomarkers are undergoing investigations as well. How can pathologists ensure that immuno-oncology biomarker testing is carried out according to best practices, and collaborate with oncologists and other members of the cancer care team in interpreting the results to guide therapeutic decisions for patients with cancer? In this activity, based on a recent CME/MOC/CC-certified symposium held during the 2019 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) held in National Harbor, Maryland, a panel of experts discuss the latest clinical advances with cancer immunotherapies and the research underway to further refine biomarker testing and maximize the use of checkpoint inhibitors and combinations across a broad spectrum of malignancies. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations across the spectrum of solid and liquid cancers, Describe evidence supporting the use of PD-L1, MMR/MSI, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances, Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes, Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations, Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer.
Go online to PeerView.com/XQR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses the role of novel therapeutic options in overcoming challenges associated with the management of patients with refractory rheumatoid arthritis. Upon completion of this activity, participants should be better able to: Recognize challenges associated with the management of refractory rheumatoid arthritis, Identify novel therapeutic options for rheumatoid arthritis in the context of mechanism of action, efficacy, and safety, Employ current evidence and expert recommendations into individualized treatment plans for patients with rheumatoid arthritis who have not achieved adequate disease control on previous therapies.
Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.
Go online to PeerView.com/EWW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Melanoma was the first clinical setting in which the use of immune checkpoint inhibitors was validated, leading to their rapid integration into the management of advanced disease. More recently, checkpoint inhibitors, based on phase 3 evidence, have claimed a role in the adjuvant setting. The future of adjuvant therapy for high-risk resectable melanoma is bright, but achieving optimal care will depend on close collaboration between oncologists and surgeons, as well as the identification of patients who are excellent candidates for immune-based adjuvant therapy. In this activity, based on a recent live symposium, experts in oncology get to the heart of why immunotherapy is a rational and potent management strategy for patients with high-risk, resected melanoma, offer insights into the key studies that validated adjuvant immunotherapy in resectable disease, as well as clarify what the evidence from these trials means for the practice of surgical oncology. The panel of leading experts also synthesizes the clinical experience with adjuvant checkpoint inhibition and detail practical patient identification, dosing, and safety considerations that will make a difference in how you manage your patients. Upon completion of this activity, participants should be better able to: Describe the clinical role and rationale for use of immune-based therapy in stage III, resectable melanoma, Cite updated efficacy and safety findings regarding immune checkpoint inhibitors as an adjuvant option in surgically resected melanoma, including high-risk stage III disease, Recommend the use of adjuvant immunotherapy for eligible patients with resectable stage III melanoma, Manage immune-related and immune-mediated adverse events in patients with melanoma treated with immunotherapy after surgical resection.
Go online to PeerView.com/CXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The best practices for management of patients with EGFR-mutant NSCLC continue to evolve as a result of advances in molecular testing and targeted treatment. Understanding what, when, and how to test, as well as how to select therapy, throughout the continuum of advanced NSCLC is paramount. In this activity, based on a recent live symposium held in San Diego, California, experts in EGFR-mutant NSCLC provide a concise but comprehensive overview of all the recent key evidence and new research directions and provide practical guidance for how to navigate clinical decisions in EGFR-mutant NSCLC in different settings and patient populations. Upon completion of this activity, participants will be able to: Discuss the latest recommendations for tissue- and blood-based molecular testing to evaluate EGFR mutation status in patients with advanced/metastatic NSCLC, Assess the characteristics, safety/efficacy profiles, and indications of the different EGFR inhibitors available for the treatment of EGFR-positive NSCLC in different settings and patient populations, including those with brain or leptomeningeal metastases, Evaluate the current evidence related to the mechanisms of acquired resistance to the various EGFR TKIs used in the first line and subsequent therapy of advanced EGFR-mutant NSCLC, Implement best practices related to molecular testing for EGFR mutations through the continuum of advanced NSCLC, and interpret results to guide treatment selection, Implement evidence-based, individualized treatment plans for patients with EGFR-mutant NSCLC.
Go online to PeerView.com/NCE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in allergy and dermatology discuss advances in the management of allergic and inflammatory diseases presented at the 2019 American Academy of Dermatology Annual Meeting and the American Academy of Allergy, Asthma & Immunology 2019 Annual Meeting. Upon completion of this activity, participants will be able to: Describe the relationship between type 2 inflammatory disorders, including atopic dermatitis, asthma, chronic rhinosinusitis and nasal polyps (CRS/NP), and eosinophilic esophagitis (EoE), Discuss emerging data related to the efficacy and safety of therapies for the treatment of allergic and inflammatory diseases, Apply the latest clinical data to the treatment of patients with allergic and inflammatory disorders, such as atopic dermatitis, asthma, CRS/NP, and EoE.
Go online to PeerView.com/QAJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in myeloma offer guidance on the selection and sequencing of innovative therapies for the ASCT-eligible patients with multiple myeloma, and address several ongoing clinical questions from the choice of novel induction and maintenance options to minimal residual disease monitoring and the use of newer therapeutic platforms for post-transplant relapsed disease. Upon completion of this activity, participants should be better able to: Summarize evidence regarding the safety, efficacy, and current clinical role of emerging and established regimens in conjunction with autologous stem cell transplantation (ASCT) in the management of multiple myeloma, Develop personalized induction and post-ASCT maintenance/consolidation regimens with novel components for eligible patients with multiple myeloma, Select novel therapeutics for the management of relapsed multiple myeloma post-ASCT.
Go online to PeerView.com/SXH860 to view the entire program with slides. In this activity, based on a live symposium held during the 2019 Transplantation and Cellular Therapy (TCT) Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in hematology-oncology explore new developments related to the changing clinical consensus for managing veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) as a post-transplant complication. In this program, the panelists will share their views on VOD pathophysiology and proposed revisions to diagnostic and severity grading criteria, while providing guidance on practical issues related to the selection and use of novel treatments for VOD. Ultimately, the experts present a picture of modern VOD management in which diagnoses can be accurately and rapidly made and where a diversity of disease presentations (including in adult and pediatric patients) can be effectively treated. Upon completion of this activity, participants should be better able to: Describe new evidence on VOD/SOS pathophysiology, risk factors, diagnostic criteria, and disease severity grading, Cite factors that may signal the development of multi-organ dysfunction in patients with VOD/SOS, Confirm a diagnosis of VOD/SOS throughout the clinical spectrum, including late-onset disease or disease presenting with or without organ dysfunction in adult and pediatric populations, Utilize effective, timely treatment for patients with confirmed VOD/SOS, including those exhibiting multi-organ dysfunction or failure.
Go online to PeerView.com/ZGE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy (TCT) Meetings in Houston, Texas, experts in hematology and oncology explore the science behind adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells and discuss exciting new developments with this innovative approach as well as its clinical potential and role in managing relapsed/refractory hematologic malignancies, including in the context of hematopoietic stem cell transplantation (HCT). The expert panel also shares personal experiences from their practice or research on relevant patient cases to guide learners on how to effectively impact treatment care and improve outcomes for patients with leukemia and lymphoma. Upon completion of this activity, participants should be better able to: Summarize the anticancer mechanism and the latest evidence on the efficacy and safety of adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in various lymphoma and leukemia settings, Assess the clinical role and benefits of CAR-T cell therapy within the context of HCT in eligible patients with leukemia and lymphoma, Apply appropriate strategies to manage the unique safety issues associated with CAR-T cell therapy in leukemia and lymphoma.
Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they’re used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn’t have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.
Go online to PeerView.com/XYM860 to view the entire program with slides. This activity utilizes a “CaseBook” format, offering learners a collection of patient case scenarios from the experts’ personal repertoire paired with analyses of how the treatment landscape in acute and chronic graft-versus-host disease (GVHD) is evolving. Hematology-oncology and bone marrow transplant professionals take a deep dive into the underlying immunology of GVHD and the latest evidence with innovative therapeutics while also obtaining expert perspectives on the practical application of these advancements as prophylaxis or for treatment of acute and chronic, steroid–nonresponsive, and previously untreated GVHD. Upon completion of this activity, participants should be better able to: Describe the underlying immunology of post-transplant GVHD, and the rationale for and mechanisms of novel therapies in the management of GVHD, Discuss the latest evidence on novel therapies, including JAK 1/2 inhibitors, BTK inhibitors, and T-cell costimulation modulators, for prophylaxis or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HSCT setting, Apply the most optimal evidence-based strategies, including enrollment in clinical trials, for post-transplant GVHD care based on individual patient and disease characteristics.
Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.
Go online to PeerView.com/WPW860 to view the entire program with slides. In this activity, an expert in multiple myeloma discusses newer safety and efficacy data surrounding novel and emerging therapeutic drug classes for multiple myeloma, including agents directed against intracellular targets and immune-based treatment. The activity will also include expert insights on how to develop effective, individualized treatment strategies with novel components that are informed by clinical findings and how to manage treatment-related adverse effects associated with emerging agent classes. Upon completion of this activity, participants should be better able to: Cite updated data about the efficacy and safety of novel agent classes and next-generation therapeutics in multiple myeloma, including proteasome inhibitors, IMiDs, novel antibodies, immunotherapies, and epigenetic agents, among others, Develop customized therapy for patients with newly diagnosed multiple myeloma, including elderly patients, individuals eligible or ineligible for stem-cell transplant, and those requiring maintenance therapy post-transplant, Select regimens adapted to the needs of patients with previously treated multiple myeloma, including those with early relapse or relapsed/refractory multiple myeloma, Manage treatment-related adverse events in patients with multiple myeloma receiving therapy with novel or next-generation agent classes.
Go online to PeerView.com/PPP860 to view the entire program with slides. In this activity, an expert in multiple sclerosis discusses available disease-modifying therapies and strategies for shared decision-making for patients with multiple sclerosis. Upon completion of this activity, participants should be better able to: Recognize the mechanisms of action of disease-modifying therapeutic options for patients with multiple sclerosis, Apply available data on disease-modifying therapies when managing patients with multiple sclerosis, Employ evidence-based strategies designed to facilitate shared decision-making and maintain a therapeutic alliance with patients with multiple sclerosis.
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes
Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden
Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes
The Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle: Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies
Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?
Systemic Juvenile Idiopathic Arthritis: A Closer Look at the Burden on Patients and Caregivers From Diagnosis to Treatment
Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes
Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution
Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice
Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy–Related Adverse Effects in the Emergency Department
Examining the IPF Patient’s Journey to Diagnosis, Appropriate Therapy, and Overall Individualized Care
A MasterClass on New Avenues in Asthma Management: Finding the Right Patients for Targeted Therapies
An Expert Analysis of New Data for Uncontrolled Persistent Asthma Treatments: Clinical Updates From Paris